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Abstract
Giant axonal neuropathy (GAN) is caused by loss of function of the gigaxonin protein. On a cellular level GAN is
characterized by intermediate filament (IF) aggregation, leading to a progressive and fatal peripheral neurop-
athy in humans. This study sought to determine if re-introduction of the GAN gene into GAN-deficient cells and
mice would restore proper cytoskeleton IF homeostasis. Treatment of primary skin fibroblast cultures from three
different GAN patients with an adeno-associated virus type 2 (AAV2) vector containing a normal human GAN
transgene significantly reduced the number of cells displaying vimentin IF aggregates. A proteomic analysis of
these treated cells was also performed, wherein the abundance of 32 of 780 identified proteins significantly
changed in response to gigaxonin gene transfer. While 29 of these responding proteins have not been directly
described in association with gigaxonin, three were previously identified as being disregulated in GAN and
were now shifted toward normal levels. To assess the potential application of this approach in vivo and even-
tually in humans, GAN mice received an intracisternal injection of an AAV9/GAN vector to globally deliver the
GAN gene to the brainstem and spinal cord. The treated mice showed a nearly complete clearance of peripherin
IF accumulations at 3 weeks post-injection. These studies demonstrate that gigaxonin gene transfer can reverse
the cellular IF aggregate pathology associated with GAN.
Introduction
Giant axonal neuropathy (GAN, OMIM #256850) is arare chronic neurodegenerative disease characterized by
enlarged axons with disordered microtubules and interme-
diate filaments, which is fatal by the third decade of life. The
disease pathology is due to homozygous loss-of-function
mutations in the GAN gene, which encodes the protein giga-
xonin. Onset of symptoms is usually 3–4 years of age, with a
slightly awkward gait. By the end of the second decade of life,
patients normally are wheelchair bound with limited use of
the arms and little to no use of their legs. Death normally
occurs in the second or third decade of life. Peripheral nerve
biopsies from humans show enlarged axons with densely
packed and disorganized microtubules and intermediate fil-
aments (IFs) (Demir et al., 2005; Nalini et al., 2008). The dys-
function and degeneration of peripheral nerves is attributed
to this pathology. These same studies showed white matter
abnormalities in the brain by magnetic resonance imaging,
indicating an involvement of the central nervous system. This
peripheral nerve pathology (enlarged axons densely filled
with neurofilaments) serves as a basis for diagnosis, which is
then confirmed by sequencing the GAN gene. There are no
statistics on the incidence of the disease, but it is considered
extremely rare.
Giant axonal neuropathy was characterized over 25 years
ago as an inborn error in intermediate filament organization
(Pena et al. 1983), which was later found to be from muta-
tions in the gigaxonin gene and resulting loss of functional
gigaxonin protein (Bomont et al., 2000). More than 40 mu-
tations have been identified in GAN patients, including de-
letions, insertions, missense and nonsense mutations, which
lead to loss of function of gigaxonin (Bomont et al., 2000,
2003; Bruno et al., 2004; Demir et al., 2005; Houlden et al.,
2007; Koop et al., 2007; Kuhlenba¨umer et al., 2002; Leung
et al., 2007). Gigaxonin is a broadly expressed Cul3 ubiquitin
ligase adaptor protein, normally present at extremely low
levels throughout the brain (Cleveland et al., 2009). Known
direct targets of gigaxonin are MAP8, MAP1B, and TCB-C,
which are involved with IF regulation (Allen et al., 2005;
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Ding et al., 2002, 2006; Wang et al., 2005). In the absence of
gigaxonin, the regulation of IFs is disrupted, leading to in-
creased IFs that can form inclusion bodies. The composition
of these inclusions varies based on the specific IF composi-
tion in any given cell type. Vimentin, peripherin, neurofila-
ments (NF-H, NF-M, NF-L), alpha-internexin, GFAP, nestin,
desmin, and keratin are IFs known to accumulate in mice
and/or humans lacking gigaxonin (Berg et al., 1972; Dequen
et al., 2008; Pena et al., 1983). Abnormal aggregates of keratin
in hair are likely responsible for the typical curled hair ob-
served in most patients (Bomont and Koenig, 2003; Pena
et al., 1983; Prineas et al., 1976). The vimentin aggregates in
fibroblasts are located in the perinuclear space close to the
microtubule organizing center (Bomont and Koenig, 2003).
Gigaxonin is also a substrate for ubiquitination and degra-
dation by its own Cul3 ubiquitin ligase complex, providing a
level of self-regulation at the protein level (Zhang et al., 2005).
Unfortunately, the underlying function(s) of gigaxonin
and the mechanism by which the protein regulates IFs is
poorly understood. The structural/functional domains of
gigaxonin include an N-terminal BTB domain (BR-C, ttk, and
bab), a centrally located conserved BACK domain, and six
kelch motifs in the C-terminal part. Gigaxonin has a sus-
pected role as a substrate-specific adaptor for the BCR (BTB/
Kelch protein-cullin-3-RING box protein1) E3 ubiquitin li-
gase complex (Furukawa et al., 2003). As such an adaptor, it
may facilitate proteasome targeting and degradation of vari-
ous substrate proteins such as MAP1B, MAP8, and TBC-B
via interactions with its C-terminal kelch domains (Ding
et al., 2002, 2006; Wang et al., 2005). It has been postulated
that these substrates accumulate in the absence of gigaxonin,
and this hypothesis was partly confirmed in GAN knock-out
(KO) mice (Allen et al., 2005; Ding et al., 2006; Wang et al.,
2005) but not in human cells (Cleveland et al., 2009). How-
ever, no direct link has been established to explain how this
leads to disregulation of IFs.
Conceptually, the unbalanced regulation of IFs could be
corrected by re-introducing gigaxonin. In such a scenario, it
is also conceivable that restoring normal IF regulation could
allow cells to resolve IF inclusions and reverse existing pa-
thology. Carriers of mutant gigaxonin alleles (humans and
mice) express approximately 50% levels of gigaxonin and are
phenotypically and pathologically normal, suggesting that
restoration of lower-than-normal gigaxonin levels could still
be efficacious. While gross overexpression of gigaxonin has a
conceptual risk for toxicity, the protein-level autoregulation
of gigaxonin abundance should correct for mild over-
expression. Therefore, a broad therapeutic index of gigaxonin
expression levels is expected. For these reasons, we propose
that GAN is an excellent candidate for a gene replacement
therapy. This study sought to determine if re-introduction of
gigaxonin into GAN-deficient cells would restore proper
cytoskeleton IF homeostasis, reversing the cellular disease
phenotype of IF aggregation. In this study, skin fibroblast
cultures from three different GAN patients were transduced
with an adeno-associated virus type 2 (AAV2) vector con-
taining a normal human GAN transgene or a green fluorescent
protein (GFP) transgene as a control. Reduction in vimentin
aggregation following viral delivery was scored microscopi-
cally. To further characterize the global intracellular changes
associated with gigaxonin re-introduction, the proteome of
these cells was analyzed after viral delivery, identifying and
measuring the relative abundance of proteins using a differ-
ential proteomics method based on the iTRAQ strategy in
combination with two-dimensional liquid chromatography
mass spectrometry (2D-LC-MS) on a MALDI TOFTOF MS
platform. Finally, to assess the potential application of this
approach in vivo and eventually in humans, GAN-KO mice
were injected with an AAV9/GAN vector and scored for re-
duction of the neuronal IF peripherin in the brainstem and
spinal cord. This study sought to understand intracellular
changes that occur in response to the re-introduction of
gigaxonin into GAN-null cells, both in vitro and in vivo.
Methods
Patients fibroblast cultures
Primary skin fibroblasts were maintained in MEM-alpha
(Gibco no. 12561) containing penicillin and streptomycin
with 10% fetal bovine serum (FBS), at 5% CO2 and 37C. P1
has a homozygous missense mutation (p. Ala49Glu), P2 has
heterozygous mutations (p. S52G and C393X), and P3 has a
homozygous deletion (c.1647-8680_*258del, encompassing
exons 10 and 11). These patients were all clinically verified to
be GAN patients with typical symptoms. P2 was described
previously (Bomont et al., 2000), and an Ala49Thr (similar to
P1) has been described (Bruno et al., 2004). The normal hu-
man fibroblast line was transformed with hTERT.
Vector preparation
rAAV vectors were produced using a triple-transfection
method in HEK293 cells as previously described (Gray et al.,
2011a). Highly pure recombinant virus was recovered using
sequential step and continuous CsCl gradients, then the peak
fractions were dialyzed in phosphate-buffered saline (PBS)
containing 5% D-sorbitol. Viral titers were determined by dot
blot or quantitative polymerase chain reaction (qPCR) as
described (Gray et al., 2011a). The recombinant vectors in
these studies were single-stranded AAV using AAV2 in-
verted terminal repeats, packaged in either an AAV2 or
AAV9 capsid. The CMV-GAN construct used a cytomega-
lovirus (CMV) enhancer/promoter, myc-tagged gigaxonin
coding sequence, and SV40 polyA. The GFP construct used
the same CMV enhancer/promoter, enhanced GFP coding
sequence, and SV40 polyA.
Vector treatments in vitro, immunocytochemistry, and
vimetin aggregate scoring
For proteomic analysis, cells were grown in 10 cm plates.
Cells were seeded 2.5 · 105 per plate, in triplicate to three
plates. After 1 day, 5 · 1010 vector genomes (vg) of either
ssAAV2/CMV-GAN or ssAAV2/CMV-GFP were added to
each plate. Three days post-infection, cells were harvested
with trypsin, washed with PBS, and cell pellets were frozen
at - 80 C until use.
For immunocytochemistry, 10,000 cells per well were
seeded onto poly-L-lysine coated coverslips (BD no. 354085)
in 24-well plates on day 0. On day 1, 5· 109 vg of AAV2
vector, or a corresponding amount of PBS containing 5%
sorbitol, was added per well. On day 2 the media was
changed. On days 4–5 (3–4 days post-infection), cells were
washed with PBS and fixed with 4% paraformaldehyde for
10min at room temperature. Cells were then washed with
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PBS and incubated twice for 10min at room temperature
with PBS containing 0.1% Triton-X100. Blocking was done
for 1 hr at room temperature with PBS containing 3% goat
serum and 0.1% Triton-X100. Primary antibody incubation
was for 1 hr at room temperature with PBS containing 3%
goat serum, 0.1% Triton-X100, 1:1000 dilution of mouse anti-
vimentin (Millipore no. CBL202), and 1:500 dilution of rabbit
anti-GFP (Millipore no. 3080). After three washings with PBS
containing 0.1% Triton-X100, secondary antibody incubation
was for 1 hr in PBS containing 3% goat serum, 0.1% Triton-
X100, goat anti-mouse Alexa594 (Invitrogen no. A11032),
and goat anti-rabbit Alexa488 (Invitrogen no. A11008).
After washing twice with PBS, coverslips were mounted
onto slides using ProLong Gold Antifade mounting media
with 4¢,6-diamidino-2-phenylindole (DAPI; Invitrogen no.
P-36931). The presence of vimentin aggregates were scored
visually, with >500 cells typically assessed per coverslip.
qPCR analysis of vector genomes and gigaxonin
mRNA expression
RNA was recovered from the cells using the RNA Mini
Plus kit (Qiagen); tissue lysis was performed with the Tis-
sueLyser (Qiagen), and automated purification was carried
out on a Qiacube (Qiagen). RNA was treated to remove any
residual genomic DNA as follows: RNA was incubated for
10min at 37C with 20U Protector RNase Inhibitor (Roche),
1 · DNase I reaction buffer (NEB) and 2U of DNase I (NEB).
This was followed by an additional incubation of 10min at
75C with EDTA added to a final concentration of 2.5mM for
DNaseI inactivation. cDNAwas synthesized from the purified
RNA using the Transcriptor First Strand cDNA Synthesis kit
(Roche), following the manufacturer’s instructions, then used
directly as template for reverse transcription (RT)-qPCR. RT-
qPCR amplifications and analysis were carried out on a Roche
Lightcycler 480, following the manufacturer’s instructions and
as described (Gray et al., 2010). All primer sets used SyBR
green for quantitation except for the GAPDH primer, which
used a primer and hydrolysis probe combination.
To quantify the myc-tagged gigaxonin transgene separate
from the endogenous gigaxonin, primers were designed so
that the upstream primer annealed to the myc tag. An in-
ternal set of gigaxonin primers were also used that would
equally recognize the endogenous and transgene gigaxonin.
qPCR of cDNA samples was used to determine the absolute
numbers of myc-gigaxonin, total gigaxonin, and GAPDH
transcripts per unit volume in each sample. Transcript
quantification is reported as the absolute number of giga-
xonin transcripts per microliter divided by the absolute
number of actin transcripts per microliter in the sample.
Primers for myc-tagged human gigaxonin were as follows:
FORWARD: 5¢-tgatcagcgaggaggacctgg-3¢; REVERSE: 5¢-
gttgatccatcatcttttggagg-3¢. Internal gigaxonin primers recog-
nizing the endogenous and transgene gigaxonin were as
follows: FORWARD: 5¢-ggttatgagagagatcctgga-3¢; REVERSE:
5¢-cgtgatggaggcagtaatgta-3¢. The human GAPDH reactions
use the following primers and probe: FORWARD: 5¢-agcca
catcgctcagacac-3¢; REVERSE: 5¢-gcccaatacgaccaaatcc-3¢;
PROBE: UPL#60 (Roche cat no. 04688589001). A melting
curve analysis was performed at the end of each SyBR green
qPCR run, following the manufacturer’s instructions, to
verify the purity of the PCR product.
iTRAQ reagent labeling and peptide separation
Proteins were extracted by resuspending each cell pellet in
200lL of lysis buffer, containing 0.05 M triethyl ammonium
bicarbonate, 7 M urea, 2 M thiourea, and protease inhibitor
cocktail (Roche). The cells were sonicated, and the superna-
tant was collected after centrifugation at 13,000· g for 20min
at 4C. An acetone precipitation was performed prior to the
protein concentrations measurement by the Bradford protein
assay (Thermo Scientific). A summary of the experimental
workflow is shown in Supplementary Figure S2 (Supple-
mentary Data are available online at www.liebertpub.com/
hum). Equal amounts of protein (25 lg) from each cell lysate
were used. The iTRAQ labeling was performed according to
the manufacturer’s protocol using solvents included in the kit
(AB SCIEX). The six peptide samples were added to the dif-
ferent labels of the 8-plex iTRAQ kit (AB SCIEX) as follows:
patient 1 (P1), 113 (GAN) and 114 (GFP); patient 2 (P2), 115
(GAN) and 116 (GFP); and patient 3 (P3), 117 (GAN) and 118
(GFP). The labels were added in excess to obtain full labeling.
Labeling was confirmed for all samples before combining
the samples. After combining the six iTRAQ-labeled samples,
the mixture was vacuum dried and dissolved in 20mM
HCOONH4, 2% acetonitrile (ACN) at pH 10.
The labeled peptide mixture was separated on an Ettan
liquid chromatography system (GE Healthcare), using a Luna
C18 column (2.0mm i.d.· 150mm length· 5lm, 100 A˚ col-
umn; Phenomenex), as described by Mussche et al. (2012). The
buffer compositions were 20mM HCOONH4, 2% ACN at pH
10 for buffer A and 20mMHCOONH4, 80% ACN at pH 10 for
buffer B. The flow rate was 0.2mL/min, and the elution gra-
dient was as follows: 7min 100% A, 60min 0%–50% B, 15min
50%–100% B, 10min 100% B, and 3min 100% A. Fractions
were collected every minute. After drying, the fractions were
redissolved in 0.1% formic acid for nano-LC/MS analysis.
Nano-LC/MS analysis
Off-line LC-MS was done as described by Mussche et al.
(2012). Briefly, analytical reversed phase separation of the la-
beled peptide mixture was performed on an Ultimate Plus
Dual-gradient Capillary/Nano-LC system (Dionex-LC Pack-
ings) using a C18 column (75lm i.d.· 150mm length, 3lm,
100 A˚; Dionex) at a flow rate of 250nL/min. The mobile
phases were 5% ACN/0.05% trifluoroacetic acid (TFA), pH 3
for buffer A and 80% ACN/0.05% TFA, pH 3 for buffer B.
Peptides were resolved by gradient elution using a gradient of
0%–50% buffer B over 25min, 50%–100% buffer B over 10min,
5min of 100% buffer B, and 10min of 100% buffer A. Fractions
were collected every 30 sec directly on a MALDI target plate.
The MALDI plates were analyzed by a 4800+ MALDI-TOF-
TOF Proteomics Analyzer (AB SCIEX). A plate calibration was
performed using the 4700 calibration mixture with a mass
tolerance of 0.5 m/z. The MSMS mode was calibrated with a
mass tolerance of 0.1 m/z. Additionally, MS spectra were in-
ternally calibrated with Glu-fibrinopeptide (1552.62 m/z). MS
data were acquired in the reflector positive mode over a mass
range of 900–3500 m/z, by accumulation of 1000 laser shots per
spectrum. The eight highest precursor masses in each MS
spectrum with an S/N threshold of minimum 50, were se-
lected for fragmentation, and the fraction-to-fraction mass
tolerance was set to 200ppm. MS/MS data were acquired
with 2000 laser shots per spectrum, using 1keV collision
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energy and air as the collision gas. Each plate was analyzed
twice by reinterpretation of the MS spectra with a method
containing an exclusion list from initial MS/MS data to avoid
analyzing peptides more than once.
Database searching and data analysis
Data analysis was performed with the software package
Mascot Daemon (Perkins et al., 1999; version 2.3, Matrix
science). All MS/MS spectra were processed against the
UniProtKB/SwissProt Homo sapiens database. Search param-
eters included iTRAQ labeling at the N-terminus and lysine
residues, cysteine modification by methyl methanethiosulfo-
nate, digestion by trypsin (including two missed cleavages
allowed), and methionine oxidation as a variable modifica-
tion. Normalization of the ratios was performed by the me-
dian ratio. A significance threshold of p< 0.05 was used for
peptide identification and an ion score cutoff of 30. Only un-
ique peptides were selected for quantification, and protein
ratios were calculated by the weighted average of the peptide
ratios. Using the build in decoy function, searching a concat-
enated database containing both forward and shuffled decoy
sequences, allowed estimation of the false discovery rate
(Reidegeld et al., 2008). The ratio of GAN/GFPwas considered
in the three patients and accepted as significant regulated
when the ratios of all three patients samples showed a sig-
nificant value at the 95% confidence level ( p< 0.05).
The function, interactions and localization of the differ-
ential regulated proteins were studied based on information
in databases such as Uniprot, neXtProt, and STRING (Snel
et al., 2000), only considering experimentally confirmed in-
teractions.
Western blotting of fibroblast samples
For validation of the proteins found by iTRAQ, fibroblast
protein extracts of each sample (proteins sonicated in lysis
buffer) were separated by tricine-SDS-PAGE on a 16.5%
polyacrylamide gel. Proteins were transferred by electro-
blotting (3 hr at 60V) onto a nitrocellulose membrane (In-
vitrogen). Immunoblotting was carried out with primary
antibodies against the galectin-1 (ab25138, Abcam), PARK7/
DJ1 (Abcam ab18257), and b-actin (Abcam). The intensity of
the protein bands was quantified using the Quantity One
imaging software (Bio-Rad).
Mouse studies
All investigations were approved by the University of
North Carolina–Chapel Hill Institutional Animal Care and
Use Committee. Ten microliters of ssAAV9/CMV-GFP
(8 · 1010 vg) or ssAAV9/CMV-GAN (7.2 · 1010 vg) vector
were injected into the cisterna magna. The AAV9/GFP in-
jections were done in 19–20 month-old heterozygous GAN
mice, and the ssAAV9/GAN injections were done in KO
GANDex1 (Dequen et al., 2008) or GANDex3–5 (Ding et al., 2006)
mice. Three weeks following vector injection, each mouse
was sacrificed and transcardially perfused with PBS or PBS
containing 1U/mL heparin (Abraxis).
Immunohistochemistry to detect peripherin aggregates
After 48 hr of fixation in freshly made PBS with 4%
paraformaldehyde, the entire brain and portions of the cer-
vical and lumbar spinal cords were sectioned at 40lm using
a Leica vibrating microtome. Every fifth section was pro-
cessed for immunohistochemistry (IHC). Samples were in-
cubated for 1 hr at room temperature in blocking solution
(10% goat serum, 0.1% triton X-100, 1 · PBS), then incubated
48–72 hr at 4C in primary antibody solution (3% goat serum,
0.1% triton X-100, 1 · PBS, and primary antibody). Primary
antibodies were as follows: rabbit anti-GFP (Millipore no.
AB3080, 1:500), rabbit anti-peripherin (Millipore no. AB1530,
1:500), mouse anti-neurofilament heavy chain (NF-H, Cov-
ance no. SMI-32P, 1:1000). After washing three times in PBS,
secondary amplification was performed using a VectaStain
ABC Elite Kit (Vector Labs, no. PK-6101 for rabbit and PK-
6102 for mouse, as appropriate) with 3,3¢-diaminobenzidine
tetrachloride (DAB; Polysciences, Inc. no. 04008) substrate
and nickel-cobalt intensification of the reaction product.
DAB-processed brain sections were digitized using a Scan-
Scope slide scanner (Aperio Technologies). Virtual slides
were viewed using ImageScope software package (v. 10.0;
Aperio Technologies), which allowed sections to be viewed
at equivalent magnifications.
Western blot of mouse tissue
To validate expression of the gigaxonin transgene follow-
ing intracisternal vector delivery, a small portion of the cau-
dal brainstem was homogenized and subjected to SDS-PAGE,
then blotted. The myc-tagged gigaxonin band was detected
with a goat anti-gigaxonin antibody (N-18, Santa Cruz no.
49688, 1:300) or a mouse anti-myc antibody (Millipore no. 05–
724, 1:1000).
Results
Reduction of vimentin aggregates following gigaxonin
gene transfer
The first part of this study sought to investigate the effects
of AAV/gigaxonin gene transfer into GAN patient fibro-
blasts, in terms of the IF organization and potentially broader
effects on the proteome (Fig. 1). Dermal fibroblasts taken
from human GAN patients show cytoskeletal disorganiza-
tion and aggregation of the IF vimentin when grown in
culture, and these accumulations may be enhanced by cul-
turing them in low serum media (0.1% FBS) or growing cells
to confluence for 3 days (Bomont and Koenig, 2003). We
have observed that when these cells are grown on poly-L-
lysine coated coverslips the accumulations are enhanced
even in 10% FBS-containing media. Untransformed fibro-
blasts from three GAN patients and a normal human fibro-
blast line were seeded, then infected the next day with
AAV2 vectors (CMV-GFP, CMV-GAN, or PBS ‘‘mock’’) at an
multiplicity of infection (MOI) of 5· 104 vg/cell. The media
was changed 24 hr after infection and then the cells were
grown in complete media (10% FBS) for an additional 2–3
days (3–4 days post-infection). Cells were then fixed and
immunolabeled for vimentin, and the percentage of vimentin
aggregate-containing cells were scored.
Approximately 53% of the fibroblasts were transduced
(average of nine trials, range 30% to 71%), as gauged by the
number of cells GFP-positive in the AAV2/GFP control
group. No suitable anti-gigaxonin antibodies were available to
immuno-label for cells expressing the gigaxonin transgene,
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and immunocytochemistry against the myc tag also failed to
detect the gigaxonin protein. Treatment with the AAV2/GAN
vector resulted in a significant reduction in the percentage of
cells containing vimentin aggregates, as compared to the
mock-infected and AAV2/GFP-infected cells (Fig. 2). Analysis
of the mRNA from the cells by RT-qPCR indicated a 3.8-, 1.1-,
and 12.4-fold (P1, P2, and P3 respectively) average increase in
gigaxonin mRNA in GAN-treated patient cells versus mock-
treated patient cells. The amount of gigaxonin mRNA seen in
mock-treated patient cells was equivalent when comparing P1
and P2 to normal human fibroblasts, but the P3 mRNA levels
were lower. This is understandable since P1 and P2 had
missense mutations that were unlikely to affect the mRNA
expression and stability, whereas P3 had a homozygous de-
letion at the 3¢ end of the gene. The overall average amount of
gigaxonin mRNA in GAN-treated cells was 6.2-, 2.6-, and 5.7-
fold (P1, P2, and P3 respectively) above that detected in nor-
mal human fibroblasts. These results indicated that gigaxonin
was being mildly overexpressed at 3 days post-infection in
this experiment.
There was a small decrease in the overall number of fi-
broblasts following the AAV2/GAN treatment, suggesting
the possibility of overexpression-related toxicity, but it isn’t
clear if this was due to the gigaxonin gene or high doses of
AAV used ( p = 0.03 compared to mock treatment and p= 0.69
compared to GFP treatment, Supplementary Fig. S1). No
vimentin aggregates were observed in any of the normal
human fibroblasts, and no obvious change in vimentin was
observed in the normal human fibroblasts following
AAV2/GAN treatment. These results indicate that giga-
xonin can function to reduce vimentin IF aggregations and
restore normal vimentin organization within 3–4 days of
infection.
Proteome analysis
Currently, there is an incomplete understanding of the
cellular function of gigaxonin, and gaps of knowledge exist
regarding both its direct binding partners and its down-
stream targets. To assess the more global consequence of
gigaxonin re-introduction into GAN patient fibroblasts, we
undertook a proteomic analysis of the cells following AAV2/
GAN or AAV2/GFP gene transfer. Protein extracts from the
total cell lysate from six cultured fibroblast cell line samples
(three GAN-infected and three GFP-infected patient cultures)
were trypsinized and iTRAQ-labeled, followed by reversed
phase (RP)-RP LC and MALDI-TOFTOF MS/MS analysis for
identification and quantitation. All RP-LC MALDI-TOFTOF
runs were searched against the UniProtKB Homo sapiens
database, resulting in identification of 14,460 peptides lead-
ing to 780 proteins. Proteins with all six iTRAQ labels were
considered in the final list. The iTRAQ protein ratios re-
ported here are weighted averages calculated from the ratios
of the individual peptides determined for each protein with
the accompanying SD and p value. From the total of 780
proteins identified with > 95% confidence, 31 proteins were
found to be significantly regulated ( p< 0.05) between GAN-
and GFP-transfected cells in all three patients (Table 1).
Changes seen between different samples will not be due to
any AAV-specific effects since each AAV2/GAN-treated
culture was compared with an AAV2/GFP-treated culture
from the same patient.
The differentially regulated proteins were further analyzed
according to their function, interaction and localization, based
on information in databases such as UniProt, neXtProt, and
STRING (Snel et al., 2000). Some possible interesting interac-
tions with components of the ubiquitin-proteosome system
are listed in Supplementary Table S1. A set of proteins pre-
viously described to be differentially regulated in GAN pa-
tients versus controls was found not altered in response to the
AAV2/GAN treatment (Supplementary Table S2). A list of all
proteins detected is provided as Supplementary Table S3.
Interestingly, we found no change in the overall levels of vi-
mentin in response to the AAV2/GAN treatment.
Western blot analysis was performed to validate results
obtained from the proteome analysis. Galectin-1 and DJ-1
were selected, as according to the iTRAQ results these were
significantly down-regulated following gigaxonin gene
transfer, and galectin-1 was previously shown to be over-
expressed in GAN patients compared to controls (Mussche
et al., 2012). This means that this is probably an important
player in GAN. Even though the degree of reduction de-
tected in the proteomic analysis was modest (0.62–0.88 fold
compared to the GFP treatment), the Western blot results
confirmed the down regulation of galectin-1 and DJ-1 in the
transduced fibroblasts (Fig. 3).
FIG. 1. Study design. (A) Diagram of the packaged single-
stranded rAAV genomes used in these studies. (B)Workflow
for in vitro experiments using normal (NHF) or GAN patient
(GAN) fibroblasts. rAAV, recombinant adeno-associated vi-
rus; GAN, giant axonal neuropathy.
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In vivo rescue of peripherin IF aggregates following
central nervous system AAV9/GAN gene transfer
To assess the possible translational potential of an AAV/
GAN vector, a similar experiment to the in vitro vimentin IF
rescue was undertaken in vivo. There are three KO mouse
models described for GAN (Dequen et al., 2008; Ding et al.,
2006; Ganay et al., 2011). The first was described as recapit-
ulating many of the human disease symptoms, but subse-
quent rigorous analysis of all three mouse models have
shown that the mice do not develop any behavioral, motor,
or sensory deficits until > 12 months of age, and these effects
are fairly modest (Ganay et al., 2011). However, these mouse
models do display IF aggregates that are a hallmark of the
underlying disease pathology, including aggregations of
neurofilaments, alpha-internexin, and peripherin in the cen-
tral nervous system (CNS) that are visible as early as 3
months of age (Dequen et al., 2008).
In this experiment, we introduced the GFP or GAN gene
into two of the GAN-KO mouse models (GANDex1 and
GANDex3–5) when these mice were 17–21 months old (see
Supplementary Table S4 for a list of subjects and results
summary). Under anesthesia, mice received a single injection
into the cerebrospinal fluid of the cisterna magna. Ten mi-
croliters (7.2 · 1010 total vg) of AAV9/CMV-GAN was in-
jected into KO mice or 10 lL (8· 1010 total vg) of AAV9/
CMV-GFP was injected into age-matched heterozygous
mice, then the mice were allowed to recover. When injected
into the cisterna magna in mice, AAV9 efficiently transduces
large areas of the brainstem, dorsal spinal cord, motor neu-
rons in the ventral horn, and to a much lesser extent other
areas of the brain as visualized with GFP (Fig. 4A–C). In the
absence of a good behavioral readout in these mice for a
phenotypic rescue of function, a histological evaluation of IF
aggregate resolution was pursued. Three weeks post-injec-
tion with the AAV9/CMV-GAN vector, mice were sacrificed
for IHC evaluation of the IF aggregates in the brain. No IHC
was done against gigaxonin because no suitable antibodies
are available and IHC against the myc epitope failed. We
observed nearly complete clearance of peripherin aggregates
in the brainstem and dorsal lumbar spinal cord, in both the
GANDex1 and GANDex3–5 KO mice (Fig. 4D–F, Supplementary
Figs. S3 and S4). As expected, heterozygous mice did not
show any abnormal peripherin staining and homozygous
KO mice showed consistent and extensive aggregates of
peripherin, at ages ranging from 8 to 24 months
FIG. 2. Reduction of vimentin aggregates after AAV/gigaxonin gene transfer. Cultured GAN patient fibroblasts were
treated with in parallel with vehicle buffer (mock), AAV2/GAN vector (GAN), or AAV/GFP vector (GFP), then fixed and
immunostained for vimentin after 3–4 days. (A) Representative images of cells with (right) or without (left) the vimentin
aggregate phenotype. Vimentin is red and 4¢,6-diamidino-2-phenylindole (DAPI) is blue. (B) Vimentin aggregates were
manually scored, and the average percentage of cells containing vimentin aggregates plotted. Three different lines were used:
P1 (n = 5, blue bars), P3 (n= 4, red bars), and P2 (n = 2, green bars). (C) An additional set of cells was collected to assess relative
level of gigaxonin expression by mRNA analysis after 3 days. ‘‘GAN (total)’’ used primers that recognize endogenous and
exogenous gigaxonin, and ‘‘myc-GAN’’ used primers that only recognize the exogenously delivered gigaxonin. Error
bars = SEM; p values calculated using a Student’s t test, one-tailed, unequal variance.
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(Supplementary Table S4). Expression of exogenous myc-
tagged human gigaxonin in the brainstem was verified by
Western blot analysis of brainstem tissue from treated mice,
compared to heterozygous or untreated KO mice of similar
age (Fig. 4G). The amount of gigaxonin in treated mice
compared to heterozygous controls indicated a higher de-
gree of overexpression in the mice at 3 weeks post-infection
compared to the mild overexpression seen in fibroblasts at 3
days post-infection (compare WB in Fig. 4G to Fig. 2). Al-
though the study investigated peripherin aggregates in age-
matched KO mice, and in some cases littermates, we wanted
to verify to the best extent possible that the treated mice had
IF aggregates pre-injection and that these were resolved as a
result of the AAV9/GAN treatment. Because areas of the
midbrain and forebrain were not efficiently targeted by
AAV9 via this route of administration, they were stained for
peripherin (midbrain, dorsal raphe nucleus) and neurofila-
ment-heavy chain (NF-H, cortex and striatum) to investigate
the presence of IF aggregates in these areas. Despite the
absence of peripherin aggregates in the brainstem and dor-
sal spinal cord, the treated mice still had peripherin aggre-
gates in the dorsal raphe nucleus and NF-H aggregates in
the cortex and striatum (Supplementary Fig. S5). Although
a comprehensive histopathological evaluation was not
done on these mice, they did not display any adverse be-
havior phenotypes or gross brain pathology as a result of the
treatment. These data provide strong evidence that the
AAV9/GAN vector was capable of resolving long-standing
peripherin IF aggregates in the CNS.
Discussion
As a whole, these experiments provide critical proof-of-
concept data that re-introduction of gigaxonin into affected
GAN-null cells resolves IF aggregates, which are a major
hallmark of the underlying disease pathology in mice and
Table 1. Differentially Regulated Proteins Between GAN-Transfected and GFP-Transfected GAN Patients
Acc. no.a Protein name %b nc P1d P2e P3f Localization
O15145 Actin-related protein 2/3 complex subunit 3 19.1 6 1.29 1.61 1.33 Cytoskeleton
P60981 Destring 47.3 6 0.85 0.47 0.51 Cytoskeleton
Q14315 Filamin-Cg 24 26 1.30 1.44 1.12 Cytoskeleton
P60660 Myosin light polypeptide 6g 66.9 11 0.77 0.83 0.61 Cytoskeleton
Q01995 Transgeling 84.6 30 0.81 0.47 0.65 Cytoskeleton
O75347 Tubulin-specific chaperone Ag 45.4 4 0.63 0.82 0.49 Cytoskeleton
P63104 14-3–3 protein zeta/deltag 60 7 0.76 0.63 0.76 Cytoplasm
P15880 40S ribosomal protein S2 29.7 4 1.24 1.23 1.21 Cytoplasm
P36578 60S ribosomal protein L4 42.9 10 1.18 1.28 1.54 Cytoplasm
P23588 Eukaryotic translation initiation factor 4Bg 27.3 6 0.55 0.80 0.72 Cytoplasm
Q15056 Eukaryotic translation initiation factor 4Hg 16.1 4 0.52 0.80 0.61 Perinuclear
P09211 Glutathione S-transferase Pg 30 10 0.74 0.67 0.89 Cytoplasm
O43795 Myosin-Ib 16.5 6 1.18 1.61 1.31 Cytoplasm
Q99497 Protein DJ-1g 32.8 7 0.74 0.62 0.65 Cytoplasm
P52565 Rho GDP-dissociation inhibitor 1g 43.1 5 0.75 0.41 0.66 Cytoplasm
P39656 Dolichyl-diphosphooligosaccharide–protein
glycosyltransferase 48-kDa subunitg
15.7 5 1.48 1.66 1.70 ER
P04843 Dolichyl-diphosphooligosaccharide–protein
glycosyltransferase subunit 1g
12.4 6 1.57 1.79 1.26 ER
O95302 FK506-binding protein 9 20 7 1.37 1.24 1.15 ER
P55072 Transitional endoplasmic reticulum ATPaseg 41.2 20 1.42 1.25 1.17 ER
P23284 Peptidyl-prolyl cis-trans isomerase Bg 68.5 18 1.45 1.52 1.17 ER
P09382 Galectin-1 63 28 0.88 0.82 0.65 Extracellular cytoplasm
P15144 Aminopeptidase N 11.3 9 1.63 1.41 1.16 Extracellular membrane
P16070 CD44 antigeng 7.5 6 1.36 1.47 1.30 Membrane
Q00610 Clathrin heavy chain 1g 21.9 24 1.31 1.10 1.43 Membrane
Q9NZM1 Myoferlin 14.3 8 1.36 1.45 1.27 Membrane
O00469 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 17.5 4 1.41 1.50 1.33 Membrane RER-membrane
O60568 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 19.4 4 1.50 1.64 1.17 Membrane RER- membrane
Q6NUK1 Calcium-binding mitochondrial carrier
protein SCaMC-1
6.9 5 1.08 1.41 1.60 Mitochondrial inner
membrane
Q9H1E3 Nuclear ubiquitous casein and cyclin-dependent
kinases substrate
15.6 6 0.68 0.80 0.81 Nucleus
P22392 Nucleoside diphosphate kinase Bg 50 7 0.89 0.71 0.74 Nucleus
Q9H299 SH3 domain-binding glutamic acid-rich-like
protein 3g
53.8 5 0.67 0.84 0.77 Nucleus
aUniprot accession number.
bPercentage of protein sequence coverage.
cNumber of peptides.
dPatient 1, ratio of GAN-transfected to GFP-transfected cells ( p< 0.05).
ePatient 2, ratio of GAN-transfected to GFP-transfected cells ( p< 0.05).
fPatient 3, ratio of GAN-transfected to GFP-transfected cells ( p < 0.05).
gProteins identified in this study but not altered between GAN patients and controls (Mussche et al., 2012).
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humans. This was demonstrated in vitro in cultured GAN-
null fibroblasts with the IF vimentin and in vivo in GAN-null
mice with the IF peripherin. Moreover, the proteomic anal-
ysis of treated GAN primary fibroblasts provides important
information with regards to more global changes (besides
IFs) that occur in treated cells, which provides further in-
sights into both the mechanism of the rescue and the basic
biology of gigaxonin’s function. While several reasonable
conclusions can be drawn from these studies, the results
should be considered within the appropriate context; namely
that gigaxonin was overexpressed using the CMV promoter.
Also, for the proteomic analysis, it is important to consider
that this analysis was restricted to a single time point of 3
days post-infection. The timing was restricted to allow en-
ough time for gigaxonin expression without prolonged
maintenance of the dividing fibroblast culture (which would
dilute transgene-expressing cells). Our results indicated that
gigaxonin may play a role in multiple pathways affecting
cytoskeleton regulation, and thus it may take longer than
practical for an in vitro experiment to observe all proteome-
level changes, especially for proteins with long half-lives.
Therefore we can only interpret the presence of proteome-
level changes, but not the absence of change.
Proteome analysis
Mussche et al. (2012) had previously done a proteomic
analysis of GAN patient fibroblasts compared to normal
control fibroblasts. One interesting finding is that three
proteins that were previously found to be disregulated in
GAN patients compared to healthy controls again showed
altered expression levels in the AAV2/GAN-treated cells,
only the regulation was seen in the other direction towards
normal levels. This is the case for galectin-1, aminopeptidase
N (APN), and FK506-binding protein 9. Interestingly, a set of
proteins previously found to be differentially regulated in
GAN patients versus controls was not found to be altered
in response to the AAV2/GAN treatment (Supplementary
Table S2). Those results would suggest that while some of
the disregulated proteins in GAN can rapidly return to ho-
meostatic levels in response to gigaxonin reintroduction,
other changes may take longer to correct or may represent
irreversible changes. However, since the proteomic changes
in our experiment can be correlated to resolution of IF ag-
gregates within the 3- to 4-day experimental timeframe, we
can speculate that the proteins that modulated in response to
gigaxonin reintroduction are important in the GAN disease
mechanism. In particular a role for galectin-1 was previously
proposed for GAN, as a regulator of cytoskeleton reorgani-
zation (Mussche et al., 2012). The FK506BP9 belongs to the
FK506BP family, which comprises peptidyl prolyl isomerases
that function as protein-folding chaperones and are also in-
volved in the aggregation process of alpha-synuclein clusters
in Parkinson disease (Gerard et al., 2012). APN is a trans-
membrane zinc-binding metallo-ectopeptidase that removes
amino acids from unblocked N-termini of bioactive peptides
or proteins. It plays a role in cell migration and invasion of
extracellular matrix, angiogenesis, and regulation of extrinsic
regulatory factors of tumor growth, all conditions in which
remodeling of the cytoskeleton is required. The introduction
of the correct GAN-gene will activate several processes in
reaction to this new gene, which is reflected in up- or down-
regulation of a set of proteins (Table 1). The majority of the
differentially regulated proteins in the present study were
previously identified in the proteomic analysis done by
Mussche et al., but were not found to be disregulated in GAN
fibroblasts (indicated in Table 1; Mussche et al., 2012). This
may indicate that they are associated with GAN over-
expression, rather than a return to a normal state. Some of
these proteins were found to be associated with several
ubiquitin specific peptidases (Sowa et al., 2009), and the
ubiquitin-proteasome system, as listed in Supplementary
Table S1. Ubiquitin-specific peptidases are a class of deubi-
quitinating enzymes that help to regulate many cellular
processes by controlling the amount of the protein ubiquitin,
through removing ubiquitin from a large variety of sub-
strates (D’Andrea and Pellman, 1998; Wilkinson, 2000). But
FIG. 3. Western blot validation of changes in protein levels.
Western blot experiments were performed on protein ex-
tracts of fibroblasts after treatment with AAV vectors. (A)
Representative Western blot analysis for proteins DJ-1 and
galectin-1. (B, C) Densities of the bands were first measured
and normalized against actin for each lane; values are the
average from three Western blots. Then ratios were calcu-
lated by dividing the actin-normalized GAN value by the
actin-normalized GFP value for each patient. A p value was
calculated based on the ratios of the three patients in the
three Western blots. For both DJ-1 and galectin-1 the changes
were significant ( p < 0.05). DJ-1 and galectin-1 were down-
regulated in GAN-transduced cells compared to GFP-trans-
duced cells, consistent with the iTRAQ proteomics results
(Table 1). The validity of actin as a loading control was jus-
tified by its unchanged expression in GAN patients (Bomont
et al., 2000; Pena et al., 1983). GAN = treated with AAV2/
CMV-GAN; GFP = treated with AAV2/CMV-GFP. Error
bars are SD.
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targets, interactions, and specific functions of deubiquitinat-
ing enzymes are poorly understood. However, it is possible
that in response to GAN overexpression they play a com-
pensatory role by deubiquitination of targeted proteins.
Since GAN fibroblasts don’t display a rise in the overall
abundance of vimentin (Mussche et al., 2012) and there was
no change in overall vimentin levels following AAV2/GAN
treatment (Supplementary Table S3), we can speculate that
the absence (and re-introduction) of gigaxonin is affecting
the cytoskeletal organization of vimentin, rather than its total
intracellular levels. The reduction of vimentin aggregates
seen in transduced GAN fibroblasts indicates that there is a
fairly rapid reorganization of the cytoskeleton. Several dis-
regulated proteins were found associated with cytoskeleton
reorganization (Table 1). Actin-related protein 2/3 complex
subunit 3 functions as a component of the Arp2/3 complex,
which is involved in the regulation of actin polymerization
and, together with an activating nucleation-promoting fac-
tor, mediates the formation of new branched actin networks.
This is important during centrosome re-orientation before
cytokinesis and in cytoskeletal organization. Destrin is an
actin-depolymerizing protein, which severs actin filaments
(F-actin) and binds to actin monomers (G-actin) and profi-
lin4. Transgelin is an actin-crosslinking protein found in fi-
broblasts and muscle. The abundance of cytoskeleton
proteins that were found changed in response to gigaxonin
re-expression in this study reinforces gigaxonin’s role in cy-
toskeleton organization, but a full model for all the interac-
tions and pathways still remains elusive.
Another pertinent observation is the up-regulation of
several endoplasmic reticulum resident proteins in GAN-
treated fibroblasts, in particular enzymes involved in protein
FIG. 4. Resolution of peripherin aggregates in GAN mice. Wild-type (WT) C57Bl/6J mice were injected with 8 · 1010 vector
genomes (vg) ssAAV9/CMV-GFP into the cerebral spinal fluid (CSF) of the cisterna magna, then GFP expression was
assessed in the forebrain (A), brainstem (B), and lumbar spinal cord (C) by immunohistochemistry (IHC) against GFP. (C–F)
The 17- to 21-month-old GANDex1 (n= 2) or GANDex3–5 (n = 2) mice were injected with 7.2 · 1010 vg of ssAAV2/CMV-GANv2
vector into the CSF of the cisterna magna. Three weeks post-injection the mice were sacrificed and sections of their brain and
spinal cord assayed for peripherin accumulations by IHC. Results shown are indicative of all mice per group (see Supple-
mentary Table S4 for a summary of all mice examined). Columns D–F: top panel shows the spinal trigeminal nucleus of the
brainstem and the bottom set of panels show the dorsal lumbar spinal cord. Column D shows the IHC against peripherin in a
normal mouse. Column E shows the pattern in a knock-out (KO) GAN mouse, and Column F shows mice of the same age
treated with the vector. (G) Western blot brainstem tissue from a KO GAN mouse (KO, showing no gigaxonin), a hetero-
zygous GAN mouse showing the low level of endogenous gigaxonin expression, and a treated KO GAN mouse expressing
the myc-tagged gigaxonin transgene. The top row of bands are blotted with an anti-gigaxonin antibody, and the bottom row
is a blot done in parallel with an anti-myc tag antibody. Samples are run in duplicate. Scale bars in panels A–F indicate
micrometers. Larger annotated images are available as Supplementary Data.
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synthesis, maturation, and post-translational modification,
in addition to enzymes involved in endocytosis and re-
cycling. This reflects a general return to a functional state of
the fibroblast.
Potential for GAN gene therapy
GAN is a progressively fatal sensory and motor neuro-
pathy. It begins with the loss of distal motor and sensory
function, and as the disease progresses into the teenage years
individuals will gradually lose the ability to walk and use
their arms. The disease is normally fatal in the third decade
of life, often due to respiratory dysfunction or other com-
plications normally associated with a motor neuron disease.
While GAN patients will display IF cytoskeletal disorgani-
zation in many cell types in their body, successful treatment
of the spinal cord and brainstem would be hypothesized to
treat the most serious disease phenotypes.
AAV9 vector administration into the vein, lumbar intra-
thecal space, and cisterna magna have all been validated as
ways to achieve broad CNS transgene delivery in large an-
imal models (Duque et al., 2009; Federici et al., 2012; Gray
et al., 2013). In the present study, cisterna magna injections
were modeled in mice to investigate a potential therapeutic
approach for GAN that might be translatable to humans.
Although the behavioral phenotype of these mice is very
mild and therefore not amenable to assess a phenotypic
rescue, they do display extensive IF aggregates. En-
couragingly, there was widespread resolution of peripherin
aggregates throughout the brainstem and spinal cord at
3 weeks following vector delivery. Considering that IF ac-
cumulations (including peripherin) are present as early as
3 months of age in GAN mice (Dequen et al., 2008), this result
demonstrates the ability of the gigaxonin gene to resolve
long-standing IF aggregates that are a hallmark of the dis-
ease pathology in vivo.
While the present studies implicate gigaxonin for a role in
cytoskeleton organization, future studies are still needed to
understand the exact cellular pathways affected by giga-
xonin. In terms of a future gene therapy for GAN, the
present study indicates the potential of gigaxonin gene re-
placement as a therapeutic approach for GAN. However,
the use of a strong promoter and a single-stranded AAV
genome is not ideal. Since gigaxonin is normally expressed
at very low levels (Cleveland et al., 2009), overexpression-
related toxicity is a concern and our studies suggest this
possibility (see indicated changes in Table 1 and Supple-
mentary Fig. S1), so a weak promoter may be sufficient and
preferred. Self-complementary (sc)AAV vectors would
greatly increase the transduction efficiency with AAV (Gray
et al., 2011b; McCarty et al., 2003), which could be critical for
human translation, although the 1.9-kb size of the gigaxonin
gene may be challenging to fit in a*2.2-kb scAAV genome
with the appropriate transcriptional control elements. We
speculate that these improvements would play an impor-
tant role in the translation of these findings to future human
application.
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